Do analysts prefer CALT or ORGO?

Organogenesis has a consensus target price of $5.75, indicating a potential upside of 136.63%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Organogenesis is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ORGO or MPLT?

In the previous week, Maplight Therapeutics had 5 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Maplight Therapeutics and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.63 beat Maplight Therapeutics' score of -0.27 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ORGO or XERS?

In the previous week, Organogenesis and Organogenesis both had 1 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Organogenesis' score of 0.63 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, COAG or ORGO?

Organogenesis has higher revenue and earnings than Hemab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Organogenesis $564.17M 0.55 $37.03M -$0.19 N/A

Does the media prefer COAG or ORGO?

In the previous week, Hemab Therapeutics had 14 more articles in the media than Organogenesis. MarketBeat recorded 15 mentions for Hemab Therapeutics and 1 mentions for Organogenesis. Hemab Therapeutics' average media sentiment score of 1.05 beat Organogenesis' score of 0.63 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ORGO or AKTS?

Organogenesis has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.55 $37.03M -$0.19 N/A Aktis Oncology $8.28M 174.27 N/A N/A N/A

Does the media favor ORGO or AKTS?

In the previous week, Organogenesis and Organogenesis both had 1 articles in the media. Aktis Oncology's average media sentiment score of 1.38 beat Organogenesis' score of 0.63 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organogenesis (ORGO) Competitors

$2.43 0.00 (0.00%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$2.44 +0.01 (+0.41%)

As of 07:38 AM Eastern

Compare

ORGO vs. CALT, MPLT, XERS, COAG, and AKTS

Should you buy Organogenesis stock or one of its competitors? MarketBeat compares Organogenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organogenesis include Calliditas Therapeutics AB (publ) (CALT), Maplight Therapeutics (MPLT), Xeris Biopharma (XERS), Hemab Therapeutics (COAG), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does Organogenesis compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organogenesis has a consensus target price of $5.75, indicating a potential upside of 136.63%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Organogenesis is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Organogenesis has a net margin of -0.84% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Organogenesis' return on equity of 9.63% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, Organogenesis had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Organogenesis and 0 mentions for Calliditas Therapeutics AB (publ). Organogenesis' average media sentiment score of 0.63 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Organogenesis	Positive

Organogenesis has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Summary

Organogenesis beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Maplight Therapeutics?

Organogenesis (NASDAQ:ORGO) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Maplight Therapeutics had 5 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Maplight Therapeutics and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.63 beat Maplight Therapeutics' score of -0.27 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organogenesis has higher revenue and earnings than Maplight Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Maplight Therapeutics	N/A	N/A	N/A

49.6% of Organogenesis shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Organogenesis currently has a consensus price target of $5.75, suggesting a potential upside of 136.63%. Maplight Therapeutics has a consensus price target of $38.00, suggesting a potential upside of 32.68%. Given Organogenesis' higher possible upside, equities research analysts plainly believe Organogenesis is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Organogenesis beats Maplight Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Xeris Biopharma?

Organogenesis (NASDAQ:ORGO) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Organogenesis has higher revenue and earnings than Xeris Biopharma. Organogenesis is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00

In the previous week, Organogenesis and Organogenesis both had 1 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Organogenesis' score of 0.63 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Xeris Biopharma has a net margin of 3.81% compared to Organogenesis' net margin of -0.84%. Xeris Biopharma's return on equity of 735.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Xeris Biopharma	3.81%	735.00%	3.24%

Organogenesis presently has a consensus price target of $5.75, suggesting a potential upside of 136.63%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 50.00%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Organogenesis has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Summary

Xeris Biopharma beats Organogenesis on 8 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Organogenesis (NASDAQ:ORGO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Organogenesis has higher revenue and earnings than Hemab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Organogenesis	-0.84%	9.63%	4.76%

49.6% of Organogenesis shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics presently has a consensus target price of $41.40, suggesting a potential upside of 42.02%. Organogenesis has a consensus target price of $5.75, suggesting a potential upside of 136.63%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Hemab Therapeutics had 14 more articles in the media than Organogenesis. MarketBeat recorded 15 mentions for Hemab Therapeutics and 1 mentions for Organogenesis. Hemab Therapeutics' average media sentiment score of 1.05 beat Organogenesis' score of 0.63 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organogenesis beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Organogenesis compare to Aktis Oncology?

Organogenesis (NASDAQ:ORGO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aktis Oncology has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Aktis Oncology	N/A	N/A	N/A

Organogenesis presently has a consensus target price of $5.75, indicating a potential upside of 136.63%. Aktis Oncology has a consensus target price of $34.00, indicating a potential upside of 25.88%. Given Organogenesis' higher probable upside, equities analysts plainly believe Organogenesis is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Organogenesis has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A
Aktis Oncology	$8.28M	174.27	N/A	N/A	N/A

In the previous week, Organogenesis and Organogenesis both had 1 articles in the media. Aktis Oncology's average media sentiment score of 1.38 beat Organogenesis' score of 0.63 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organogenesis and Aktis Oncology tied by winning 6 of the 12 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$312.68M	$2.96B	$6.44B	$12.30B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-12.79	18.43	24.65	23.99
Price / Sales	0.55	343.38	535.11	118.14
Price / Cash	3.76	56.31	44.82	54.51
Price / Book	1.03	4.11	10.70	6.50
Net Income	$37.03M	$64.45M	$3.56B	$336.88M
7 Day Performance	3.85%	1.41%	0.94%	-0.16%
1 Month Performance	-8.65%	1.04%	0.35%	0.76%
1 Year Performance	-29.77%	23.88%	29.67%	28.49%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	2.2404 of 5 stars	$2.43 flat	$5.75 +136.6%	-27.2%	$312.68M	$564.17M	N/A	950
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
MPLT Maplight Therapeutics	3.583 of 5 stars	$27.96 +0.8%	$37.78 +35.1%	N/A	$1.18B	N/A	N/A	109	News Coverage Analyst Forecast Gap Down
XERS Xeris Biopharma	3.322 of 5 stars	$6.88 +1.3%	$10.80 +57.0%	+55.2%	$1.17B	$291.85M	114.67	290
COAG Hemab Therapeutics	4.7938 of 5 stars	$25.08 +0.4%	$41.75 +66.5%	N/A	$1.17B	N/A	N/A	72	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. CALT, MPLT, XERS, COAG, and AKTS

How does Organogenesis compare to Calliditas Therapeutics AB (publ)?

Summary

How does Organogenesis compare to Maplight Therapeutics?

Summary

How does Organogenesis compare to Xeris Biopharma?

Summary

How does Organogenesis compare to Hemab Therapeutics?

Summary

How does Organogenesis compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. CALT, MPLT, XERS, COAG, and AKTS

How does Organogenesis compare to Calliditas Therapeutics AB (publ)?

Do institutionals and insiders have more ownership in CALT or ORGO?

Do analysts prefer CALT or ORGO?

Is CALT or ORGO more profitable?

Does the media favor CALT or ORGO?

Which has stronger valuation & earnings, CALT or ORGO?

Which has more volatility & risk, CALT or ORGO?

Summary

How does Organogenesis compare to Maplight Therapeutics?

Does the media favor ORGO or MPLT?

Which has stronger valuation and earnings, ORGO or MPLT?

Is ORGO or MPLT more profitable?

Do institutionals and insiders hold more shares of ORGO or MPLT?

Do analysts recommend ORGO or MPLT?

Summary

How does Organogenesis compare to Xeris Biopharma?

Which has higher valuation & earnings, ORGO or XERS?

Does the media prefer ORGO or XERS?

Is ORGO or XERS more profitable?

Do analysts prefer ORGO or XERS?

Do institutionals and insiders hold more shares of ORGO or XERS?

Which has more risk and volatility, ORGO or XERS?

Summary

How does Organogenesis compare to Hemab Therapeutics?

Which has stronger earnings and valuation, COAG or ORGO?

Is COAG or ORGO more profitable?

Do insiders and institutionals hold more shares of COAG or ORGO?

Do analysts recommend COAG or ORGO?

Does the media prefer COAG or ORGO?

Summary

How does Organogenesis compare to Aktis Oncology?

Do insiders and institutionals believe in ORGO or AKTS?

Is ORGO or AKTS more profitable?

Do analysts recommend ORGO or AKTS?

Which has stronger earnings and valuation, ORGO or AKTS?

Does the media favor ORGO or AKTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools